About
ENT Treatments
Areas of Focus
Categories
Small Molecule PharmaceuticalSan Diego & Southern California
Team (14)
Allan Kirk
Allan Kirk, MD, PhD
Eledon Pharmaceuticals
team_member
Bryan Smith
Bryan Smith
Eledon Pharmaceuticals
team_member
David Hovland
David Hovland, PhD
Eledon Pharmaceuticals
team_member
David-Alexandre C
David-Alexandre C. Gros, MD
Eledon Pharmaceuticals
team_member
Eliezer Katz
Eliezer Katz, MD, FACS
Eledon Pharmaceuticals
team_member
James Robinson
James Robinson
Eledon Pharmaceuticals
team_member
Clinical Trials (6)
View allTotal Trials
6
As Lead Sponsor
5
As Collaborator
1
Total Enrollment
336
By Phase
EARLY_PHASE1: 1PHASE2: 3PHASE1/PHASE2: 2
By Status
RECRUITING: 2ENROLLING_BY_INVITATION: 1ACTIVE_NOT_RECRUITING: 1WITHDRAWN: 1TERMINATED: 1
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT06972069Collaborator
Tolerance Through Mixed Chimerism (Sip-Tego)
EARLY_PHASE1Recruiting
12 participants
Started: May 31, 2025 · Completed: Dec 31, 2030
NCT06126380Lead Sponsor
Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients
PHASE2Enrolling by invitation
132 participants
Started: Oct 25, 2023 · Completed: Dec 31, 2029
NCT05983770Lead Sponsor
Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
PHASE2Active, not recruiting
120 participants
Started: Aug 30, 2023 · Completed: Mar 31, 2025
NCT05480657Lead Sponsor
Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D
PHASE1/PHASE2Withdrawn
Started: Sep 30, 2022 · Completed: Aug 31, 2028
NCT05125068Lead Sponsor
Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)
PHASE2Terminated
24 participants
Started: Mar 21, 2022 · Completed: Jul 31, 2023
Locations (1)
Headquarters
Irvine, CA, United States
Map
Loading map...